Skip to main content
Premium Trial:

Request an Annual Quote

BioMérieux Obtains CE Mark for VIDAS 3, Plans to Pursue US FDA Approval


BioMérieux said that its VIDAS 3 immunoassay platform has received an EU CE mark, making it commercially available in Europe and other countries recognizing the CE marking.

In a statement, François Lacoste, corporate vice president of BioMérieux's immunoassay unit, said the company now plans to pursue regulatory approval for the platform in other countries – the US and China, in particular.

The VIDAS 3 is the latest in BioMérieux's VIDAS line and, the company said, offers enhanced automation, improved traceability, and new software features, as well as a quality control program that is in compliance with laboratory certification standards.

Using the same reagents as previous VIDAS instruments, the device currently offers tests for 99 clinical parameters.

According to BioMérieux, the VIDAS line has the largest installed base of automated immunoassay systems in the world, with more than 27,000 instruments in clinical labs. The company claims that it has received roughly 200 intentions to purchase the new instrument based on recent conference demonstrations.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.